It is well known that HIV‐1 primarily infects CD4+ T cells, and the infection is initiated by binding the gp120 subunit of env with CD4, which triggers a conformational change in env that allows it to interact with a host cell coreceptor protein CCR5 or CXCR4.[3a] Therefore, CD4+ T cell‐mimicking nanoparticles were designed for HIV inhibition, and their significant HIV‐1 neutralization was confirmed.[1, 12] However, these nanoparticles acquired their cell‐mimicking ability by disguising themselves with the membrane extracted from CD4+ T cells. The gene discussed is ERVW-1; the disease is infection.